HOOKIPA Pharma (HOOK) Competitors $0.83 +0.00 (+0.06%) As of 08/15/2025 03:43 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOOK vs. COEP, ACRV, CALC, PLUR, JSPR, OVID, STTK, ALXO, FGEN, and PEPGShould you be buying HOOKIPA Pharma stock or one of its competitors? The main competitors of HOOKIPA Pharma include Coeptis Therapeutics (COEP), Acrivon Therapeutics (ACRV), CalciMedica (CALC), Pluri (PLUR), Jasper Therapeutics (JSPR), Ovid Therapeutics (OVID), Shattuck Labs (STTK), ALX Oncology (ALXO), FibroGen (FGEN), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry. HOOKIPA Pharma vs. Its Competitors Coeptis Therapeutics Acrivon Therapeutics CalciMedica Pluri Jasper Therapeutics Ovid Therapeutics Shattuck Labs ALX Oncology FibroGen PepGen HOOKIPA Pharma (NASDAQ:HOOK) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Do analysts prefer HOOK or COEP? HOOKIPA Pharma currently has a consensus target price of $4.50, suggesting a potential upside of 441.19%. Given HOOKIPA Pharma's stronger consensus rating and higher possible upside, analysts clearly believe HOOKIPA Pharma is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HOOKIPA Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings and valuation, HOOK or COEP? Coeptis Therapeutics has lower revenue, but higher earnings than HOOKIPA Pharma. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHOOKIPA Pharma$9.35M1.08-$43.50M-$5.85-0.14Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.41 Does the media favor HOOK or COEP? In the previous week, HOOKIPA Pharma and HOOKIPA Pharma both had 3 articles in the media. HOOKIPA Pharma's average media sentiment score of 0.96 beat Coeptis Therapeutics' score of 0.65 indicating that HOOKIPA Pharma is being referred to more favorably in the media. Company Overall Sentiment HOOKIPA Pharma Positive Coeptis Therapeutics Positive Do institutionals & insiders have more ownership in HOOK or COEP? 63.9% of HOOKIPA Pharma shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 3.3% of HOOKIPA Pharma shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, HOOK or COEP? HOOKIPA Pharma has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.59, indicating that its stock price is 159% less volatile than the S&P 500. Is HOOK or COEP more profitable? Coeptis Therapeutics has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HOOKIPA Pharma-785.66% -120.09% -77.14% Coeptis Therapeutics N/A -216.96%-113.00% SummaryHOOKIPA Pharma beats Coeptis Therapeutics on 10 of the 14 factors compared between the two stocks. Get HOOKIPA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOOK vs. The Competition Export to ExcelMetricHOOKIPA PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.14M$3.10B$5.68B$9.81BDividend YieldN/A2.23%3.79%4.11%P/E Ratio-0.1420.8931.0825.11Price / Sales1.08366.96467.01115.26Price / CashN/A42.3037.4059.05Price / Book0.208.659.096.18Net Income-$43.50M-$54.65M$3.26B$265.11M7 Day Performance-5.57%6.56%7.36%4.21%1 Month Performance-27.06%7.53%5.47%2.01%1 Year Performance-82.89%13.69%30.61%23.74% HOOKIPA Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOOKHOOKIPA Pharma3.4628 of 5 stars$0.83+0.1%$4.50+441.2%-83.0%$10.14M$9.35M-0.14160Short Interest ↓COEPCoeptis Therapeutics0.5207 of 5 stars$11.06-0.9%N/A+236.5%$39.21MN/A-1.912Earnings ReportShort Interest ↑Gap UpACRVAcrivon Therapeutics2.99 of 5 stars$1.23-0.8%$17.71+1,340.2%-81.3%$38.88MN/A-0.5558News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionCALCCalciMedica3.3664 of 5 stars$2.76+0.7%$16.00+479.7%-29.0%$38.28MN/A-1.7730Earnings ReportShort Interest ↓Analyst RevisionGap UpPLURPluri2.252 of 5 stars$4.55-5.6%$12.00+163.7%-13.9%$37.91M$330K-0.82150Short Interest ↑Gap DownJSPRJasper Therapeutics2.9622 of 5 stars$2.63+7.3%$29.75+1,031.2%-82.8%$36.80MN/A-0.5020News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionOVIDOvid Therapeutics4.2435 of 5 stars$0.56+7.9%$3.10+457.9%-14.2%$36.61M$570K-1.5960News CoverageEarnings ReportAnalyst UpgradeShort Interest ↑Analyst RevisionGap UpSTTKShattuck Labs3.5577 of 5 stars$0.74-2.3%$7.50+914.6%-69.6%$36.23M$5.72M-0.53100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpALXOALX Oncology2.9095 of 5 stars$0.61-9.2%$3.30+437.0%-75.7%$36.14MN/A-0.2540Earnings ReportGap DownFGENFibroGen4.601 of 5 stars$8.37-3.9%$43.00+413.7%+2.6%$35.20M$29.62M-3.35570Earnings ReportAnalyst DowngradeAnalyst RevisionHigh Trading VolumePEPGPepGen3.194 of 5 stars$1.01-5.6%$7.67+659.1%-85.8%$35.10MN/A-0.3430Gap Up Related Companies and Tools Related Companies Coeptis Therapeutics Competitors Acrivon Therapeutics Competitors CalciMedica Competitors Pluri Competitors Jasper Therapeutics Competitors Ovid Therapeutics Competitors Shattuck Labs Competitors ALX Oncology Competitors FibroGen Competitors PepGen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOOK) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HOOKIPA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HOOKIPA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access